Business Trends– category –
-
Former U.S. Energy Secretary Jennifer Granholm Joins Tandem PV Board of Directors to Accelerate Perovskite-Silicon Tandem Solar Cell Commercialization
Tandem PV (via press release distribution) USA Overview Former U.S. Energy Secretary Jennifer Granholm has joined the board of directors of Tandem PV, a company developing perovskite-silicon tandem solar cells. Tandem PV was founded thro... -
Sekisui Chemical’s ‘Solafil’ Flexible Perovskite Solar Cells Officially Launched: Targeting 100MW Mass Production by 2027 with 20% Efficiency and 20-Year Lifespan
YouTube (News commentary on Sekisui Chemical) Japan Overview Sekisui Chemical announced the full-scale launch of 'Solafil,' Japan's first film-type perovskite solar cell, in March 2026. This flexible, thin, and lightweight solar cell ena... -
Halocell Energy Secures Australian Government Grant for Perovskite PV Scale-Up: Wagga Wagga Facility to Upgrade to Advanced Roll-to-Roll Equipment
Solarbytes (Halocell Energy) Australia Overview Perovskite solar cell technology manufacturer Halocell Energy has secured a significant grant from the Australian government's Industry Growth Program. This funding will be used to substant... -
Sekisui Chemical’s Perovskite Solar Cell Program Increases Capital Expenditure and Execution Risk Amidst Diversified Business Operations: A Financial Assessment
Perplexity (Sekisui Chemical Co., Ltd. related news) Japan Overview Sekisui Chemical, a diversified Japanese conglomerate with four core businesses, is seeing its perovskite solar cell program increase capital expenditure pressure and ex... -
Dexcom Reaffirms CGM Benefits for All People with Diabetes, Expands to Preventive Care with Stelo App Relaunch and Nutrisense Acquisition at ADA 2026
DexCom, Inc. USA Overview Dexcom announced favorable results from the CONNECT randomized controlled trial at ADA 2026, reaffirming CGM's benefits for non-insulin using type 2 diabetes patients. The company also launched early access to i... -
Comprehensive Review Spotlights Lipid Nanoparticles as a Transformative Drug Delivery System
International Journal of Scientific Research and Technology (Int. J. Sci. R. Tech.) India Overview The International Journal of Scientific Research and Technology has published a detailed review positioning lipid nanoparticles (LNPs) as ... -
Lonza Pioneers Adaptive Manufacturing for In Vivo mRNA-LNP Therapies, Unlocking CRISPR for Rare Diseases and Cancer Immunotherapy
BioXconomy Switzerland Overview Lonza has unveiled an adaptive manufacturing platform designed to accelerate the development and production of in vivo mRNA-lipid nanoparticle (LNP) delivery systems. This breakthrough technology promises ... -
Beyond LNPs: Polymer Delivery Systems Promise Enhanced Stability, Reduced Toxicity, and Targeted Delivery for mRNA Therapeutics
MDPI Switzerland Overview Polymer-based delivery systems are rapidly emerging as a promising alternative to conventional lipid nanoparticles (LNPs) for mRNA therapeutics. While LNPs have achieved significant clinical success, particularl... -
Sana Biotechnology to Announce Q1 Financial Results and Hypoimmune Cell Therapy Pipeline Progress at June Investor Conferences
Stock Titan USA Overview Sana Biotechnology is scheduled to present its Q1 2026 financial results and recent business updates on its hypoimmune cell therapy and in vivo gene editing platforms at multiple investor conferences in June 2026... -
Kelonia Therapeutics’ BCMA-Targeted In Vivo CAR T Therapy KLN-1010 Shows Promise for Multiple Myeloma with Updated Phase 1 ASCO Data
Kelonia Therapeutics Press Release USA Overview Kelonia Therapeutics presented updated first-in-human data from its Phase 1 inMMyCAR study of KLN-1010, a BCMA-targeted in vivo CAR T-cell therapy, at the 2026 American Society of Clinical ...
